| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| beta-Glucans | 5 | 2020 | 176 | 2.69 | Why? |
| Candidemia | 5 | 2020 | 353 | 2.39 | Why? |
| Gram-Negative Bacterial Infections | 5 | 2019 | 398 | 1.76 | Why? |
| Bacteremia | 8 | 2020 | 1372 | 1.64 | Why? |
| Gram-Negative Bacteria | 5 | 2019 | 473 | 1.50 | Why? |
| Drug Resistance, Multiple, Bacterial | 7 | 2019 | 1115 | 1.25 | Why? |
| Colistin | 3 | 2018 | 217 | 1.24 | Why? |
| Anti-Bacterial Agents | 14 | 2019 | 10083 | 1.20 | Why? |
| Fosfomycin | 1 | 2019 | 48 | 0.79 | Why? |
| Antifungal Agents | 6 | 2021 | 1828 | 0.77 | Why? |
| Wound Infection | 1 | 2019 | 66 | 0.73 | Why? |
| Enterobacteriaceae Infections | 4 | 2020 | 529 | 0.72 | Why? |
| Skin Diseases, Bacterial | 1 | 2019 | 105 | 0.72 | Why? |
| Antigens, Fungal | 1 | 2018 | 106 | 0.70 | Why? |
| Encephalitis, Tick-Borne | 1 | 2019 | 86 | 0.69 | Why? |
| Invasive Fungal Infections | 2 | 2019 | 274 | 0.66 | Why? |
| Candidiasis | 2 | 2019 | 334 | 0.65 | Why? |
| Hypoalbuminemia | 1 | 2018 | 235 | 0.60 | Why? |
| Cephalosporins | 1 | 2018 | 250 | 0.60 | Why? |
| Calcitonin | 1 | 2017 | 201 | 0.60 | Why? |
| Carbapenem-Resistant Enterobacteriaceae | 2 | 2017 | 214 | 0.59 | Why? |
| Proteoglycans | 4 | 2020 | 130 | 0.56 | Why? |
| Carbapenems | 4 | 2019 | 343 | 0.56 | Why? |
| Anti-Inflammatory Agents | 4 | 2020 | 6153 | 0.54 | Why? |
| Observational Studies as Topic | 2 | 2019 | 1887 | 0.54 | Why? |
| Staphylococcal Infections | 3 | 2020 | 1099 | 0.52 | Why? |
| Methylprednisolone | 2 | 2020 | 2107 | 0.48 | Why? |
| Antimicrobial Stewardship | 2 | 2019 | 931 | 0.48 | Why? |
| Pseudomonas Infections | 3 | 2020 | 425 | 0.40 | Why? |
| Hospitals, Teaching | 1 | 2017 | 1609 | 0.38 | Why? |
| Cost-Benefit Analysis | 1 | 2018 | 2259 | 0.37 | Why? |
| beta-Lactam Resistance | 3 | 2019 | 150 | 0.36 | Why? |
| Cardiac Surgical Procedures | 2 | 2019 | 1931 | 0.36 | Why? |
| Klebsiella Infections | 3 | 2017 | 466 | 0.35 | Why? |
| Anti-Infective Agents | 1 | 2019 | 1766 | 0.34 | Why? |
| Pseudomonas aeruginosa | 3 | 2020 | 652 | 0.30 | Why? |
| Pulmonary Aspergillosis | 2 | 2021 | 408 | 0.29 | Why? |
| Off-Label Use | 2 | 2020 | 553 | 0.27 | Why? |
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 9335 | 0.27 | Why? |
| Communicable Diseases | 1 | 2019 | 2148 | 0.27 | Why? |
| Drug Therapy, Combination | 2 | 2017 | 7268 | 0.27 | Why? |
| Postoperative Complications | 3 | 2019 | 5861 | 0.27 | Why? |
| Microbial Sensitivity Tests | 4 | 2019 | 2886 | 0.26 | Why? |
| Klebsiella pneumoniae | 3 | 2017 | 658 | 0.25 | Why? |
| Cross Infection | 4 | 2020 | 8675 | 0.23 | Why? |
| Mycology | 1 | 2021 | 37 | 0.23 | Why? |
| Enterobacter aerogenes | 1 | 2020 | 24 | 0.22 | Why? |
| Glucans | 1 | 2020 | 13 | 0.22 | Why? |
| Blood Volume | 1 | 2021 | 90 | 0.22 | Why? |
| Randomized Controlled Trials as Topic | 5 | 2019 | 10649 | 0.21 | Why? |
| Intensive Care Units | 9 | 2021 | 29594 | 0.20 | Why? |
| Enterococcus faecalis | 1 | 2020 | 126 | 0.20 | Why? |
| Italy | 14 | 2021 | 38444 | 0.20 | Why? |
| Enterococcus faecium | 1 | 2020 | 95 | 0.20 | Why? |
| Sternum | 1 | 2019 | 30 | 0.20 | Why? |
| Voriconazole | 1 | 2021 | 206 | 0.19 | Why? |
| Gram-Positive Bacterial Infections | 2 | 2020 | 323 | 0.19 | Why? |
| Clinical Studies as Topic | 1 | 2019 | 118 | 0.19 | Why? |
| Mummies | 1 | 2018 | 11 | 0.19 | Why? |
| Humans | 52 | 2021 | 930598 | 0.18 | Why? |
| Respiration, Artificial | 8 | 2021 | 22116 | 0.18 | Why? |
| Candidiasis, Invasive | 1 | 2019 | 107 | 0.18 | Why? |
| Pulmonary Gas Exchange | 1 | 2021 | 414 | 0.18 | Why? |
| Aspergillus fumigatus | 1 | 2021 | 239 | 0.18 | Why? |
| Acute Kidney Injury | 1 | 2018 | 5762 | 0.18 | Why? |
| Treatment Outcome | 14 | 2021 | 51732 | 0.18 | Why? |
| Transplantation, Haploidentical | 1 | 2017 | 53 | 0.18 | Why? |
| Thienamycins | 1 | 2018 | 72 | 0.17 | Why? |
| Schistosomiasis | 1 | 2018 | 59 | 0.17 | Why? |
| Cerebrovascular Circulation | 1 | 2021 | 340 | 0.17 | Why? |
| Molecular Conformation | 1 | 2018 | 374 | 0.17 | Why? |
| Intraabdominal Infections | 1 | 2018 | 90 | 0.17 | Why? |
| Enterobacteriaceae | 2 | 2018 | 395 | 0.17 | Why? |
| Cardiopulmonary Bypass | 1 | 2018 | 158 | 0.17 | Why? |
| Aspergillus | 1 | 2020 | 347 | 0.17 | Why? |
| Blood Culture | 1 | 2019 | 308 | 0.17 | Why? |
| Operative Time | 1 | 2018 | 450 | 0.16 | Why? |
| Staphylococcus aureus | 2 | 2020 | 844 | 0.16 | Why? |
| Pneumonia, Viral | 13 | 2021 | 243684 | 0.16 | Why? |
| Critical Illness | 7 | 2021 | 17281 | 0.16 | Why? |
| Serum Albumin, Human | 1 | 2018 | 265 | 0.15 | Why? |
| Molecular Biology | 1 | 2018 | 139 | 0.15 | Why? |
| Acinetobacter Infections | 1 | 2019 | 273 | 0.15 | Why? |
| Pulmonary Alveoli | 1 | 2021 | 867 | 0.15 | Why? |
| Acinetobacter baumannii | 1 | 2019 | 378 | 0.15 | Why? |
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2019 | 449 | 0.15 | Why? |
| Incidence | 6 | 2021 | 25622 | 0.15 | Why? |
| Superinfection | 1 | 2020 | 459 | 0.15 | Why? |
| Antiviral Agents | 4 | 2021 | 41703 | 0.14 | Why? |
| Administration, Intravenous | 1 | 2019 | 1115 | 0.14 | Why? |
| Fungi | 1 | 2018 | 471 | 0.14 | Why? |
| Streptococcus pneumoniae | 1 | 2020 | 827 | 0.14 | Why? |
| Bronchoalveolar Lavage Fluid | 2 | 2021 | 2309 | 0.14 | Why? |
| Candida | 1 | 2019 | 425 | 0.14 | Why? |
| Coronavirus Infections | 11 | 2020 | 253789 | 0.14 | Why? |
| Transplantation, Homologous | 1 | 2017 | 757 | 0.14 | Why? |
| Neutropenia | 1 | 2018 | 388 | 0.14 | Why? |
| Tissue Plasminogen Activator | 1 | 2021 | 778 | 0.14 | Why? |
| Pneumococcal Infections | 1 | 2020 | 562 | 0.13 | Why? |
| Disease Management | 4 | 2019 | 6841 | 0.13 | Why? |
| Drug Resistance, Bacterial | 3 | 2018 | 1414 | 0.13 | Why? |
| Fecal Microbiota Transplantation | 1 | 2018 | 372 | 0.13 | Why? |
| Terminology as Topic | 1 | 2019 | 546 | 0.13 | Why? |
| Endocarditis, Bacterial | 1 | 2018 | 344 | 0.13 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 711 | 0.12 | Why? |
| Positive-Pressure Respiration | 1 | 2021 | 1160 | 0.12 | Why? |
| Drug Utilization | 1 | 2017 | 619 | 0.12 | Why? |
| Urinary Tract Infections | 1 | 2018 | 534 | 0.12 | Why? |
| Administration, Oral | 1 | 2019 | 2340 | 0.11 | Why? |
| Lymphohistiocytosis, Hemophagocytic | 1 | 2020 | 800 | 0.11 | Why? |
| Structure-Activity Relationship | 1 | 2018 | 2219 | 0.11 | Why? |
| Physical Therapy Modalities | 1 | 2020 | 1090 | 0.11 | Why? |
| Sepsis | 2 | 2018 | 3517 | 0.11 | Why? |
| Drug Monitoring | 1 | 2019 | 1408 | 0.11 | Why? |
| Pulmonary Embolism | 2 | 2021 | 4775 | 0.11 | Why? |
| beta-Lactamases | 1 | 2017 | 759 | 0.11 | Why? |
| Leukocyte Count | 1 | 2021 | 3178 | 0.11 | Why? |
| Invasive Pulmonary Aspergillosis | 1 | 2018 | 634 | 0.11 | Why? |
| Killer Cells, Natural | 1 | 2021 | 2093 | 0.11 | Why? |
| Proportional Hazards Models | 2 | 2020 | 6543 | 0.11 | Why? |
| Vascular Diseases | 1 | 2019 | 846 | 0.10 | Why? |
| Acute Disease | 2 | 2021 | 6029 | 0.10 | Why? |
| Drug Design | 2 | 2019 | 2627 | 0.10 | Why? |
| Aged | 20 | 2021 | 215776 | 0.10 | Why? |
| Perception | 1 | 2020 | 2827 | 0.10 | Why? |
| Fibrinolytic Agents | 1 | 2021 | 1702 | 0.10 | Why? |
| Hydroxychloroquine | 3 | 2021 | 12447 | 0.09 | Why? |
| Bacterial Proteins | 1 | 2017 | 1318 | 0.09 | Why? |
| Prognosis | 3 | 2020 | 32490 | 0.09 | Why? |
| Female | 23 | 2021 | 380317 | 0.09 | Why? |
| Male | 22 | 2021 | 367725 | 0.09 | Why? |
| Cystic Fibrosis | 1 | 2018 | 1104 | 0.09 | Why? |
| Anti-HIV Agents | 1 | 2020 | 2209 | 0.09 | Why? |
| Tertiary Care Centers | 3 | 2020 | 8248 | 0.09 | Why? |
| Oxygen | 1 | 2021 | 3715 | 0.08 | Why? |
| Middle Aged | 19 | 2021 | 270681 | 0.08 | Why? |
| Retrospective Studies | 9 | 2021 | 105322 | 0.08 | Why? |
| Diagnostic Tests, Routine | 1 | 2018 | 2643 | 0.08 | Why? |
| Lopinavir | 1 | 2021 | 4308 | 0.08 | Why? |
| Risk Factors | 6 | 2021 | 71621 | 0.08 | Why? |
| Genetic Predisposition to Disease | 1 | 2020 | 4027 | 0.07 | Why? |
| Liver Cirrhosis | 1 | 2017 | 1810 | 0.07 | Why? |
| Hematologic Neoplasms | 1 | 2018 | 2105 | 0.07 | Why? |
| Biomarkers | 2 | 2018 | 23361 | 0.07 | Why? |
| Models, Molecular | 1 | 2018 | 7616 | 0.07 | Why? |
| Patient Safety | 1 | 2019 | 4885 | 0.07 | Why? |
| Bacterial Infections | 1 | 2017 | 2229 | 0.06 | Why? |
| Computational Biology | 1 | 2018 | 4514 | 0.06 | Why? |
| Sex Factors | 1 | 2020 | 11014 | 0.06 | Why? |
| Research Design | 1 | 2019 | 5830 | 0.06 | Why? |
| Diagnosis, Differential | 1 | 2017 | 7220 | 0.06 | Why? |
| Fever | 1 | 2019 | 7795 | 0.06 | Why? |
| Betacoronavirus | 10 | 2020 | 204454 | 0.06 | Why? |
| Prospective Studies | 4 | 2021 | 43301 | 0.06 | Why? |
| Immunocompromised Host | 1 | 2019 | 5150 | 0.06 | Why? |
| Adult | 11 | 2021 | 244371 | 0.06 | Why? |
| Europe | 1 | 2019 | 12702 | 0.06 | Why? |
| Lung | 2 | 2021 | 31049 | 0.06 | Why? |
| Nasopharynx | 1 | 2020 | 10224 | 0.05 | Why? |
| Inflammatory Bowel Diseases | 1 | 2018 | 3209 | 0.05 | Why? |
| Clinical Trials as Topic | 1 | 2019 | 7330 | 0.05 | Why? |
| Galactose | 1 | 2020 | 201 | 0.05 | Why? |
| Travel | 1 | 2019 | 7220 | 0.05 | Why? |
| Drug Resistance, Multiple, Fungal | 1 | 2019 | 45 | 0.05 | Why? |
| Mannans | 1 | 2020 | 218 | 0.05 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.05 | Why? |
| Viral Vaccines | 1 | 2020 | 7560 | 0.05 | Why? |
| Respiratory Insufficiency | 1 | 2020 | 7301 | 0.05 | Why? |
| Comorbidity | 2 | 2020 | 34796 | 0.05 | Why? |
| History, 16th Century | 1 | 2018 | 104 | 0.05 | Why? |
| History, Ancient | 1 | 2018 | 141 | 0.04 | Why? |
| Mass Screening | 1 | 2018 | 8005 | 0.04 | Why? |
| History, 18th Century | 1 | 2018 | 192 | 0.04 | Why? |
| Blood Gas Analysis | 1 | 2021 | 893 | 0.04 | Why? |
| Gentamicins | 1 | 2017 | 76 | 0.04 | Why? |
| Aged, 80 and over | 7 | 2021 | 88759 | 0.04 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.04 | Why? |
| Darunavir | 1 | 2020 | 477 | 0.04 | Why? |
| Minocycline | 1 | 2017 | 101 | 0.04 | Why? |
| HIV Protease Inhibitors | 1 | 2020 | 434 | 0.04 | Why? |
| Serum | 1 | 2018 | 294 | 0.04 | Why? |
| History, 19th Century | 1 | 2018 | 384 | 0.04 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.04 | Why? |
| Pandemics | 11 | 2020 | 389249 | 0.04 | Why? |
| Cyclophosphamide | 1 | 2017 | 387 | 0.04 | Why? |
| Aorta | 1 | 2018 | 355 | 0.04 | Why? |
| Influenza, Human | 1 | 2020 | 10779 | 0.04 | Why? |
| CD4 Lymphocyte Count | 1 | 2020 | 1517 | 0.04 | Why? |
| Peritonitis | 1 | 2017 | 217 | 0.04 | Why? |
| Chemoprevention | 1 | 2019 | 585 | 0.04 | Why? |
| Patient Outcome Assessment | 1 | 2019 | 707 | 0.04 | Why? |
| HIV Infections | 1 | 2020 | 11620 | 0.03 | Why? |
| Bone Marrow Transplantation | 1 | 2017 | 343 | 0.03 | Why? |
| Vaccination | 1 | 2019 | 19050 | 0.03 | Why? |
| Cohort Studies | 3 | 2021 | 36005 | 0.03 | Why? |
| Flow Cytometry | 1 | 2021 | 2393 | 0.03 | Why? |
| Morbidity | 1 | 2018 | 1426 | 0.03 | Why? |
| History, 20th Century | 1 | 2018 | 1282 | 0.03 | Why? |
| Hospitals, Public | 1 | 2017 | 774 | 0.03 | Why? |
| Donor Selection | 1 | 2018 | 804 | 0.03 | Why? |
| Lymphocyte Activation | 1 | 2021 | 2742 | 0.03 | Why? |
| Registries | 2 | 2021 | 12327 | 0.03 | Why? |
| History, 21st Century | 1 | 2018 | 1849 | 0.03 | Why? |
| Interferon-gamma | 1 | 2021 | 2711 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.03 | Why? |
| Mycoses | 1 | 2017 | 589 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2019 | 4260 | 0.02 | Why? |
| Macrophages | 1 | 2021 | 2784 | 0.02 | Why? |
| Propensity Score | 1 | 2017 | 2690 | 0.02 | Why? |
| Survivors | 1 | 2021 | 2619 | 0.02 | Why? |
| Tissue Donors | 1 | 2018 | 1679 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.02 | Why? |
| Lymphocytes | 1 | 2021 | 3056 | 0.02 | Why? |
| Antimalarials | 1 | 2020 | 2505 | 0.02 | Why? |
| International Cooperation | 1 | 2021 | 3436 | 0.02 | Why? |
| Cause of Death | 1 | 2020 | 4823 | 0.02 | Why? |
| Lung Diseases | 1 | 2020 | 2361 | 0.02 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.02 | Why? |
| Cities | 1 | 2017 | 4937 | 0.02 | Why? |
| Gastrointestinal Microbiome | 1 | 2018 | 1961 | 0.02 | Why? |
| Immunologic Factors | 1 | 2021 | 4206 | 0.02 | Why? |
| Neutrophils | 1 | 2021 | 5476 | 0.02 | Why? |
| Tomography, X-Ray Computed | 2 | 2021 | 25144 | 0.02 | Why? |
| Consensus | 1 | 2019 | 6345 | 0.02 | Why? |
| Survival Analysis | 1 | 2017 | 7592 | 0.02 | Why? |
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 2426 | 0.02 | Why? |
| Young Adult | 3 | 2018 | 93724 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2020 | 17020 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.01 | Why? |
| T-Lymphocytes | 1 | 2017 | 6670 | 0.01 | Why? |
| Hospitals | 1 | 2017 | 11793 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2018 | 22971 | 0.01 | Why? |
| Adolescent | 2 | 2017 | 86841 | 0.01 | Why? |
| Infant, Newborn | 1 | 2017 | 23105 | 0.01 | Why? |
| Hospital Mortality | 1 | 2020 | 22087 | 0.01 | Why? |
| Prevalence | 1 | 2017 | 25773 | 0.01 | Why? |
| Time Factors | 1 | 2018 | 31397 | 0.01 | Why? |
| Infant | 1 | 2017 | 30274 | 0.01 | Why? |
| Global Health | 1 | 2018 | 13911 | 0.01 | Why? |
| Child, Preschool | 1 | 2017 | 36283 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2017 | 43792 | 0.01 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.01 | Why? |
| Child | 1 | 2017 | 70012 | 0.01 | Why? |